Prospective in-hospital registry of patients with suspected or documented COVID-19 infection and community-acquired pneumonia (TARGET-VIP): characteristics of patients and assessment of in-hospital outcomes
https://doi.org/10.15829/1728-8800-2020-2727
Abstract
Aim. To characterize patients admitted to hospital with suspected or documented COVID-19 infection and community-acquired pneumonia (CAP) and to assess the prevalence of concomitant cardiovascular, non-cardiac diseases, prehospital cardiovascular therapy and outcomes of in-hospital treatment.
Material and methods. The TARGET-VIP registry includes patients admitted to the N. I. Pirogov National Medical and Surgical Center with suspected or documented COVID-19 infection and/or CAP for the period from April 6, 2020 to July 2, 2020. COVID-19 infection was diagnosed using polymerase chain reaction (PCR) tests and chest computed tomography (CT). Comorbid conditions and pre-hospital therapy were assessed.
Results. A total of 1,130 patients were included in the registry (mean age, 57,5±12,8 years; men, 579 (51,2%)). Using PCR test, COVID-19 infection was established in 686 (60,7%) patients; using chest CT − 334 (29,6%) patients. The most numerous were the group with a combination of COVID-19 and CAP (n=662; 58,6%) and the group with CAP without positive PCR (n=402; 35,6%). The group of patients with COVID-19 without CAP was the smallest (n=24; 2,1%); in 3,7% of patients (n=42), CAP was not confirmed and PCR were negative. The proportion of people with cardiovascular diseases (CVD) according to the survey, in comparison with data of medical records, was higher by 2% (52,2 vs 50,2%); the proportion of persons with chronic non-cardiac diseases − higher by 6,7% (50,8 vs 44,1%). Among patients with CVD (n=598), compared with patients without CVD (n=532), following diseases was diagnosed significantly more often: diabetes (odds ratio (OR), 5,66; 95% confidence interval (CI), 3,52-9,12), respiratory disease (OR, 2.,7; 95% CI, 1,43-4,27), chronic kidney disease (OR, 3,32; 95% CI, 1,97-5,59), obesity (OR, 15,35; 95% CI, 6,62-35,59). Hospital mortality was 4,2% and significantly differs (4,7 times) in patients with and without COVID-19 according to PCR (6,6 vs 1,4%, p=0,0001), including among patients with CAP and positive or negative PCR (6,0 vs 1,2%, p=0,0002).
Conclusion. COVID-19 infection was diagnosed in 60,7% of patients according to PCR and in 90,3% of patients according to the combination of PCR and chest CT. Among patients with CVD, the proportion of people with chronic noncardiac diseases was significantly higher (regardless of age and sex), in particular, with diabetes, chronic kidney disease and obesity. Questionnaires provided important data on the history of noncommunicable diseases and prehospital cardiovascular therapy. The mortality rate of patients with documented COVID-19 infection was 4,7 times higher than with undocumented.About the Authors
O. M. DrapkinaRussian Federation
Moscow
O. E. Karpov
Russian Federation
Moscow
M. M. Lukyanov
Russian Federation
Moscow
S. Yu. Martsevich
Russian Federation
Moscow
A. A. Pulin
Russian Federation
Moscow
N. P. Kutishenko
Russian Federation
Moscow
V. G. Akimkin
Russian Federation
Moscow
E. Yu. Andrenko
Russian Federation
Moscow
V. P. Voronina
Russian Federation
Moscow
V. A. Dindikova
Russian Federation
Moscow
N. A. Dmitrieva
Russian Federation
Moscow
A. V. Zagrebelny
Russian Federation
Moscow
O. V. Lerman
Russian Federation
Moscow
A. N. Makoveeva
Russian Federation
Moscow
E. Yu. Okshina
Russian Federation
Moscow
E. V. Kudryashov
Russian Federation
Moscow
V. G. Klyashtorny
Russian Federation
Moscow
A. A. Smirnov
Russian Federation
Moscow
V. S. Fomina
Russian Federation
Moscow
References
1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5.
2. Yang Y, Yang M, Shen C, et al. Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections. medRxiv. 2020.02.11.20021493. doi:10.1101/2020.02.11.20021493.
3. Ai T, Yang Z, Hou H. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology. 2020;296:E32-E40 doi:10.1148/radiol.2020200642.
4. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21. doi:10.1016/S2213-2600(20)30116-8.
5. Pass HI. Medical registries: Continued attempts for robust quality data. J Thorac Oncol. 2010;5(6 Suppl. 2):S198-9. doi:10.1097/JTO.0b013e3181dcf957.
6. Singhal R, Rana R. Intricacy of missing data in clinical trials: Deterrence and management. Int J Appl Basic Med Res. 2014;4(3):2-5. doi:10.4103/2229-516x.140706.
7. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-42. doi:10.1001/jama.2020.2648.
8. Guan W, Ni Z, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708-20. doi:10.1056/nejmoa2002032.
9. Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531-8. doi:10.1007/s00392-020-01626-9.
10. Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic. JACC. 2020;75(18):2352-71. doi:10.1016/j.jacc.2020.03.031.
11. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance. January 28, 2020 (https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf).
12. Viasus D, Cillóniz C, Cardozo CG, et al. Early, short and long-term mortality in community-acquired pneumonia. Ann Res Hosp. 2018;2:5. doi:10.21037/arh.2018.04.02.
13. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol. 2020;5(7):831-40. doi:10.1001/jamacardio.2020.1286.
14. Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802-10. doi:10.1001/jamacardio.2020.0950.
15. Aggarwal G, Cheruiyot I, Aggarwal S, et al. Association of Cardiovascular Disease With Coronavirus Disease 2019 (COVID-19) Severity: A Meta-Analysis. Curr Probl Cardiol. 2020;45(8):100617. doi:10.1016/j.cpcardiol.2020.100617.
16. Wang B, Li R, Lu Z. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging. 2020;12:6049-57. doi:10.18632/aging.103000.
17. Casas-Rojo JM, Antón-Santos JM, Millán-Núñez-Cortés J, et al. Clinical characteristics of patients hospitalized with COVID-19 in Spain: results from the SEMI-COVID-19 Registry. Rev Clínica Española. English Ed. 2020;220(8):480-94. doi:10.1016/j.rceng.2020.07.003.
18. Jin W, Guo X, Dou J, et al. Multimorbidite analysis according to sex and age towards cardiovascular diseases of adults in Northeast China. Sci Rep. 2018;8:8607. doi:10.1038/s41598-018-25561-y.
Supplementary files
Review
For citations:
Drapkina O.M., Karpov O.E., Lukyanov M.M., Martsevich S.Yu., Pulin A.A., Kutishenko N.P., Akimkin V.G., Andrenko E.Yu., Voronina V.P., Dindikova V.A., Dmitrieva N.A., Zagrebelny A.V., Lerman O.V., Makoveeva A.N., Okshina E.Yu., Kudryashov E.V., Klyashtorny V.G., Smirnov A.A., Fomina V.S. Prospective in-hospital registry of patients with suspected or documented COVID-19 infection and community-acquired pneumonia (TARGET-VIP): characteristics of patients and assessment of in-hospital outcomes. Cardiovascular Therapy and Prevention. 2020;19(6):2727. (In Russ.) https://doi.org/10.15829/1728-8800-2020-2727